Clinicians working in primary care, gynaecology and related specialties encounter perimenopause frequently. National guidance emphasises clinical diagnosis in women over 45 based on symptoms and menstrual history, with hormone tests generally not required unless another condition is suspected.
Pathophysiology and Presentation
Fluctuating oestrogen and progesterone drive irregular cycles and multisystem symptoms. The transition can span several years, with symptoms evolving.
Vasomotor, psychological, cognitive, urogenital and musculoskeletal effects are well documented.
Overlap with thyroid disease, mood disorders, migraine, cardiovascular risk and autoimmune conditions requires careful differential assessment.
Medication effects (e.g., hormonal contraception masking bleeding patterns, antidepressants modulating symptoms) and comorbidities complicate the picture.
Continuity of care helps identify patterns that single appointments may miss.
Diagnostic Approach and Red Flags
NICE recommends diagnosing perimenopause without laboratory tests in otherwise healthy women aged 45+ with typical symptoms.
Explore alternatives or co-existing conditions where indicated (e.g., thyroid function, full blood count, cardiovascular assessment).
Sparse documentation of menstrual history is a recurring theme in delayed recognition.
Accurate diagnosis supports targeted management, reduces unnecessary investigations or mental health referrals for hormonally driven symptoms, and facilitates earlier intervention for linked issues such as iron deficiency or rising cardiometabolic risk.
System Pressures
Time-constrained consultations, fragmented pathways between primary care, mental health and secondary services, variable training, and digital triage tools that may under-emphasise hormonal contributions all contribute to delays.
National strategies, including the Renewed Women’s Health Strategy, prioritise midlife pathways, community hubs and improved education.
Internal links:
Clinical Guidance Summary: Differential Diagnosis in Midlife Women
Medicines Safety in Perimenopause Governance and
Patient Safety in Women’s Health
References
- NICE NG23 (updated).
- RCOG and BMS joint resources.
- NHS England Women’s Health Strategy (Renewed 2026).
- NIHR and related research on symptom impact and delays.
- NHS clinical overviews.
Mandatory disclaimer
This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed.
This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.